Shanghai Kai Kai Industry (600272) Stock Overview
Engages in the production, distribution, and sale of pharmaceutical and clothing products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
600272 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Shanghai Kai Kai Industry Company Limited Competitors
Anhui Sunhere Pharmaceutical ExcipientsLtd
Gansu Longshenrongfa Pharmaceutical IndustryLTD
Ginwa Enterprise (Group)
Qinghai Spring Medicinal Resources Technology
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥12.69 |
| 52 Week High | CN¥21.36 |
| 52 Week Low | CN¥11.03 |
| Beta | -0.10 |
| 1 Month Change | -4.15% |
| 3 Month Change | -9.87% |
| 1 Year Change | 3.68% |
| 3 Year Change | 42.26% |
| 5 Year Change | 59.82% |
| Change since IPO | -3.50% |
Recent News & Updates
Recent updates
Investors Appear Satisfied With Shanghai Kai Kai Industry Company Limited's (SHSE:600272) Prospects As Shares Rocket 30%
Dec 15
Shanghai Kai Kai Industry's (SHSE:600272) Earnings Are Weaker Than They Seem
Nov 05Shanghai Kai Kai Industry Company Limited (SHSE:600272) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable
Sep 28Shanghai Kai Kai Industry Company Limited's (SHSE:600272) 31% Jump Shows Its Popularity With Investors
Jul 24Shanghai Kai Kai Industry's (SHSE:600272) Weak Earnings May Only Reveal A Part Of The Whole Picture
Apr 05Some Shanghai Kai Kai Industry Company Limited (SHSE:600272) Shareholders Look For Exit As Shares Take 27% Pounding
Feb 28Shareholder Returns
| 600272 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.08% | 0.7% | 1.8% |
| 1Y | 3.7% | 17.6% | 24.1% |
Return vs Industry: 600272 underperformed the CN Pharmaceuticals industry which returned 17.6% over the past year.
Return vs Market: 600272 underperformed the CN Market which returned 24.1% over the past year.
Price Volatility
| 600272 volatility | |
|---|---|
| 600272 Average Weekly Movement | 2.9% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 600272 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600272's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 486 | Guangliang Liu | www.chinesekk.com |
Shanghai Kai Kai Industry Company Limited engages in the production, distribution, and sale of pharmaceutical and clothing products in China. The company engages in the wholesale and retail of traditional Chinese and Western medicines; medical devices; reagents; consumables and diagnosis; and treatment services, etc. under the Shang Lei and Yunshang life brand, as well as produces Chinese patent medicine preparations under the Jing and Que brands. It is also involved in the wholesale and retail of sweaters, cardigans, and clothing series under the Kai Kai brand, as well as school uniforms under the Mangnessen brand.
Shanghai Kai Kai Industry Company Limited Fundamentals Summary
| 600272 fundamental statistics | |
|---|---|
| Market cap | CN¥2.62b |
| Earnings (TTM) | CN¥15.79m |
| Revenue (TTM) | CN¥1.15b |
Is 600272 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600272 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.15b |
| Cost of Revenue | CN¥961.83m |
| Gross Profit | CN¥185.71m |
| Other Expenses | CN¥169.91m |
| Earnings | CN¥15.79m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 31, 2025
| Earnings per share (EPS) | 0.06 |
| Gross Margin | 16.18% |
| Net Profit Margin | 1.38% |
| Debt/Equity Ratio | 1.5% |
How did 600272 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 04:52 |
| End of Day Share Price | 2025/09/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Kai Kai Industry Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.